Skip to main content
Back
KYKOF logo

Kyowa Kirin Co., Ltd.

Data quality: 100%
Oversold
KYKOF
OTC Healthcare Drug Manufacturers - General
$12.42
$0.00 (0.00%)
Mkt Cap: 6.50B
Day Range
$12.42 $12.84
52-Week Range
$12.42 $18.00
Volume
1
50D / 200D Avg
$15.17 / $15.98
Prev Close
$12.42

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E 0.1 0.3
P/B 0.0 2.9
ROE % 7.7 3.7
Net Margin % 13.5 3.8
Rev Growth 5Y % 9.0 10.0
D/E 0.0 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $158.56
$154.18 – $163.82
 590 B 1
FY2029 $170.95
$166.23 – $176.62
 590 B 1
FY2028 $153.16
$148.94 – $158.24
 540 B 2

Key Takeaways

Revenue grew 9.00% annually over 5 years — modest growth
Debt/Equity of 0.00 — conservative balance sheet
Generating 58.96B in free cash flow
P/E of 0.10 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 8.66%
Cash machine — converts 87.86% of earnings into free cash flow

Growth

Revenue Growth (5Y)
9.00%
Revenue (1Y)0.34%
Earnings (1Y)12.07%
FCF Growth (3Y)-15.57%

Quality

Return on Equity
7.69%
ROIC8.59%
Net Margin13.49%
Op. Margin20.59%

Safety

Debt / Equity
0.00
Current Ratio2.72
Interest Coverage28.07

Valuation

P/E Ratio
0.10
P/B Ratio0.01
EV/EBITDA-2.08
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0.34% Revenue Growth (3Y) 6.04%
Earnings Growth (1Y) 12.07% Earnings Growth (3Y) -9.09%
Revenue Growth (5Y) 9.00% Earnings Growth (5Y) 6.40%
Profitability
Revenue (TTM) 497.26B Net Income (TTM) 67.10B
ROE 7.69% ROA 6.05%
Gross Margin 74.25% Operating Margin 20.59%
Net Margin 13.49% Free Cash Flow (TTM) 58.96B
ROIC 8.59% FCF Growth (3Y) -15.57%
Safety
Debt / Equity 0.00 Current Ratio 2.72
Interest Coverage 28.07 Dividend Yield 0.02%
Valuation
P/E Ratio 0.10 P/B Ratio 0.01
P/S Ratio 0.01 PEG Ratio 1.45
EV/EBITDA -2.08 Dividend Yield 0.02%
Market Cap 6.50B Enterprise Value -212.46B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 497.26B 495.56B 442.23B 398.37B 352.25B
Net Income 67.10B 59.87B 81.19B 53.57B 52.35B
EPS (Diluted) 128.18 113.06 151.01 99.66 97.39
Gross Profit 369.21B 362.95B 331.03B 311.46B 264.40B
Operating Income 102.36B 91.87B 86.44B 82.37B 61.17B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.11T 1.07T 1.03T 939.88B 921.87B
Total Liabilities 214.72B 216.55B 189.52B 177.06B 184.71B
Shareholders' Equity 894.11B 850.81B 836.42B 762.83B 737.16B
Total Debt 0.0 0.0 19.30B 21.64B 22.54B
Cash & Equivalents 218.96B 244.68B 403.08B 339.19B 335.08B
Current Assets 493.78B 504.03B 611.12B 542.19B 518.23B
Current Liabilities 181.24B 164.68B 133.24B 109.83B 109.13B

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#578 of 827
34
Value Defensive Investing (Benjamin Graham)
#693 of 709
1

Recent Activity

Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026